Jade Biosciences, Inc. (JBIO) 10-Year Financial Performance & Capital Metrics

JBIO • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutJade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.Show more

Revenue $0
EBITDA -$74M +8.6%
Net Income -$70M +7.8%
EPS (Diluted) -85.26 +15.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -74.91% -17.1%
ROIC -86.24% -35.7%
Debt/Equity 0.01 -11.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 87 (top 13%)
✓Trading at only 0.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM10.14%

EPS CAGR

10Y-

5Y-

3Y-

TTM87.73%

ROCE

10Y Avg-102.52%

5Y Avg-102.52%

3Y Avg-61.38%

Latest-80.09%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	1K	15K	68K	96K	282K
COGS % of Revenue	-	-	-	-	-
Gross Profit+	-1K	-15K	-68K	-96K	-282K
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-14%	-3.53%	-0.41%	-1.94%
Operating Expenses+	8.89M	23.01M	53.17M	81.31M	74.31M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	948K	8.02M	14.55M	17.09M	21.13M
SG&A % of Revenue	-	-	-	-	-
Research & Development	7.94M	14.99M	38.62M	64.22M	53.19M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-8.89M	-23.02M	-53.24M	-81.41M	-74.6M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-1.59%	-1.31%	-0.53%	0.08%
EBITDA+	-8.89M	-23.01M	-53.17M	-81.31M	-74.31M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-1.59%	-1.31%	-0.53%	0.09%
D&A (Non-Cash Add-back)	1K	15K	68K	96K	282K
EBIT	-9.54M	-22.96M	-51.49M	-75.47M	-69.57M
Net Interest Income+	-75K	65K	1.83M	5.95M	5.04M
Interest Income	0	65K	1.83M	5.95M	5.04M
Interest Expense	75K	0	0	0	0
Other Income/Expense	-722K	62K	1.75M	5.94M	5.02M
Pretax Income+	-9.61M	-22.96M	-51.49M	-75.47M	-69.57M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	3K	25K	56K	55K
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-9.61M	-22.96M	-51.51M	-75.52M	-69.63M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-1.39%	-1.24%	-0.47%	0.08%
Net Income (Continuing)	-9.61M	-22.96M	-51.51M	-75.52M	-69.63M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-14.00	-32.96	-73.67	-100.38	-85.26
EPS Growth %	-	-1.35%	-1.24%	-0.36%	0.15%
EPS (Basic)	-14.00	-32.96	-73.67	-100.38	-85.26
Diluted Shares Outstanding	697.44K	697.44K	699.2K	752.33K	816.63K
Basic Shares Outstanding	697.44K	697.44K	699.2K	752.33K	816.63K
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.68M	174.33M	131.5M	124.23M	80.12M
Cash & Short-Term Investments	4.57M	167.38M	129.22M	122.44M	78.62M
Cash Only	4.57M	54.2M	22.4M	23.49M	33.75M
Short-Term Investments	0	113.18M	106.82M	98.95M	44.87M
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	103K	240K	295K	250K	845K
Total Non-Current Assets+	39K	1.03M	3.8M	3.19M	215K
Property, Plant & Equipment	39K	728K	1.25M	902K	215K
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	302K	2.56M	2.28M	0
Total Assets+	4.71M	175.36M	135.3M	127.42M	80.33M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	36.19%	-0.23%	-0.06%	-0.37%
Total Current Liabilities+	1.77M	2.55M	7.78M	17.64M	3.83M
Accounts Payable	618K	1.21M	2.58M	2.4M	224K
Days Payables Outstanding	225.57K	29.39K	13.82K	9.11K	289.93
Short-Term Debt	0	192K	385K	420K	417K
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	964K	360K	3.13M	10.45M	319K
Current Ratio	2.64x	68.37x	16.90x	7.04x	20.93x
Quick Ratio	2.64x	68.37x	16.90x	7.04x	20.93x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	395K	776K	325K	70K
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	382K	705K	255K	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	13K	71K	70K	70K
Total Liabilities	1.77M	2.94M	8.56M	17.96M	3.9M
Total Debt+	0	574K	1.09M	675K	417K
Net Debt	-4.57M	-53.62M	-21.31M	-22.82M	-33.33M
Debt / Equity	-	0.00x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-118.52x	-	-	-	-
Total Equity+	2.94M	172.42M	126.74M	109.46M	76.43M
Equity Growth %	-	57.63%	-0.26%	-0.14%	-0.3%
Book Value per Share	4.22	247.22	181.27	145.49	93.60
Total Shareholders' Equity	2.94M	172.42M	126.74M	109.46M	76.43M
Common Stock	0	2K	2K	3K	3K
Retained Earnings	-13.41M	-36.39M	-87.9M	-163.42M	-233.05M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	-59K	-466K	237K	105K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.86M	-27.4M	-39.12M	-56.78M	-71.2M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-2.49%	-0.43%	-0.45%	-0.25%
Net Income	-9.61M	-22.96M	-51.51M	-75.52M	-69.63M
Depreciation & Amortization	1K	15K	68K	96K	282K
Stock-Based Compensation	0	0	0	0	0
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	777K	2.06M	4.57M	8.85M	9.32M
Working Capital Changes	974K	-6.51M	7.75M	9.8M	-11.17M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	37K	609K	1.37M	-164K	-2.17M
Cash from Investing+	0	-113.43M	6.93M	11.88M	56.03M
Capital Expenditures	0	-181K	-195K	-142K	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	8.92M	190.46M	396K	46M	25.43M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	0	0	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-7.86M	-27.58M	-39.32M	-56.92M	-71.2M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-2.51%	-0.43%	-0.45%	-0.25%
FCF per Share	-11.27	-39.54	-56.23	-75.66	-87.18
FCF Conversion (FCF/Net Income)	0.82x	1.19x	0.76x	0.75x	1.02x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-326.79%	-26.19%	-34.44%	-63.95%	-74.91%
Return on Invested Capital (ROIC)	-	-29.47%	-35.61%	-63.58%	-86.24%
Debt / Equity	-	0.00x	0.01x	0.01x	0.01x
Interest Coverage	-118.52x	-	-	-	-
FCF Conversion	0.82x	1.19x	0.76x	0.75x	1.02x

Frequently Asked Questions

Growth & Financials

Jade Biosciences, Inc. (JBIO) grew revenue by 0.0% over the past year. Growth has been modest.

Jade Biosciences, Inc. (JBIO) reported a net loss of $79.0M for fiscal year 2024.

Dividend & Returns

Jade Biosciences, Inc. (JBIO) has a return on equity (ROE) of -74.9%. Negative ROE indicates the company is unprofitable.

Jade Biosciences, Inc. (JBIO) had negative free cash flow of $32.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener